LIXT
Lixte Biotechnology Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.21
−6.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -92.8%
- EPS
- +22.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -68.1%
- EBIT
- -43.0%
- Net income
- -67.6%
- EPS
- +20.8%
- Free cash flow
- +3.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026